Characterizing response to neoadjuvant chemotherapy in invasive lobular breast carcinoma

While response to NCT in patients with ILC is uncommon, our findings demonstrate a selective benefit for patients with HER2-positive tumors and TNBC. In addition, pCR is correlated with a clear survival advantage in ILC.